The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity

The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity

Bibliographic Details
Main Authors: Kotwinski Paul, Smith Gillian, Sanders Julie, Ma Louise, Cooper Jackie, Thomas Michael, Mythen Michael (Monty) G, Jones Alison, Montgomery Hugh E, Pennell Dudley J
Format: Article
Language:English
Published: BMC 2013-01-01
Series:Journal of Cardiovascular Magnetic Resonance
id doaj-676e2eed24bd49b9bd286067e8eba8ea
record_format Article
spelling doaj-676e2eed24bd49b9bd286067e8eba8ea2020-11-25T02:13:58ZengBMCJournal of Cardiovascular Magnetic Resonance1097-66471532-429X2013-01-0115Suppl 1O9410.1186/1532-429X-15-S1-O94The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicityKotwinski PaulSmith GillianSanders JulieMa LouiseCooper JackieThomas MichaelMythen Michael (Monty) GJones AlisonMontgomery Hugh EPennell Dudley J
collection DOAJ
language English
format Article
sources DOAJ
author Kotwinski Paul
Smith Gillian
Sanders Julie
Ma Louise
Cooper Jackie
Thomas Michael
Mythen Michael (Monty) G
Jones Alison
Montgomery Hugh E
Pennell Dudley J
spellingShingle Kotwinski Paul
Smith Gillian
Sanders Julie
Ma Louise
Cooper Jackie
Thomas Michael
Mythen Michael (Monty) G
Jones Alison
Montgomery Hugh E
Pennell Dudley J
The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity
Journal of Cardiovascular Magnetic Resonance
author_facet Kotwinski Paul
Smith Gillian
Sanders Julie
Ma Louise
Cooper Jackie
Thomas Michael
Mythen Michael (Monty) G
Jones Alison
Montgomery Hugh E
Pennell Dudley J
author_sort Kotwinski Paul
title The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity
title_short The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity
title_full The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity
title_fullStr The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity
title_full_unstemmed The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity
title_sort breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (better-care) study: cmr with early gadolinium relative enhancement, but not high-sensitivity troponin t, predicts the risk of chronic anthracycline cardiotoxicity
publisher BMC
series Journal of Cardiovascular Magnetic Resonance
issn 1097-6647
1532-429X
publishDate 2013-01-01
work_keys_str_mv AT kotwinskipaul thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT smithgillian thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT sandersjulie thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT malouise thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT cooperjackie thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT thomasmichael thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT mythenmichaelmontyg thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT jonesalison thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT montgomeryhughe thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT pennelldudleyj thebreastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT kotwinskipaul breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT smithgillian breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT sandersjulie breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT malouise breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT cooperjackie breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT thomasmichael breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT mythenmichaelmontyg breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT jonesalison breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT montgomeryhughe breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
AT pennelldudleyj breastcancerearlydiseasetoxicityfromtherapywithepirubicinregimenscardiacassessmentandriskevaluationbettercarestudycmrwithearlygadoliniumrelativeenhancementbutnothighsensitivitytroponintpredictstheriskofchronicanthracyclinecardiotoxicity
_version_ 1724902944010141696

Similar Items